HOME >> BIOLOGY >> NEWS
Nasal antibiotic ointment reduces infection risk after surgery

In what may be the largest clinical trial to evaluate the effectiveness of antimicrobial agents in preventing surgical wound and hospital-based infections caused by Staphylococcus aureus, scientists at the University of Iowa and Johns Hopkins found that an antibiotic ointment, called mupirocin (moo-PIE-roe-sin), smeared inside the nose cut infection rates in half or better.

"Our results carry tremendous implications for reducing S. aureus surgical wound and other hospital-based infections, and for preventing illness and saving lives," says Trish Perl, M.D., associate professor of medicine, director of Hospital Epidemiology and Infection Control at Hopkins and an author of the study published in the June 13 issue of the New England Journal of Medicine.

Staphylococcus aureus is a widely distributed germ that normally resides in the nostrils of an estimated 25 to 30 percent of all hospitalized patients without causing harm. But it can contaminate surgical sites, causing severe and often deadly infections, especially in people with weakened immune systems, and contributing millions of dollars yearly to the costs of health care.

In the study, called MARS (for Mupirocin and the Risk of Staphyloccus aureus Infections), the researchers determined the rate of S. aureus surgical wound infections and other hospital-based infections in 4,030 adult patients who underwent various elective surgical procedures at the University of Iowa Hospitals and Clinics and the Veteran's Affairs Medical Center in Iowa City. Mupirocin antibiotic ointment, or a placebo, was applied to the inside of the nostrils twice daily for up to five days before surgery. Patients were followed for 30 days after surgery to determine if they acquired S. aureus infections.

While mupirocin ointment, made by GlaxoSmithKline, is highly effective at reducing the rate of S. aureus infections in patients undergoing surgery, as with any antibiotic, there is the risk of widespread r
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
12-Jun-2002


Page: 1 2

Related biology news :

1. Nasal contribution to breathing with exercise: The effect of race and gender
2. Could A Nasal Vaccine Finally Get Rid Of The Black Death?
3. Study Shows Athletes Get No Kick From Nasal Strips
4. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
5. Smart antibiotics may result from UCLA research
6. K-State researcher working to improve alternatives to equine antibiotics
7. Bacterial protein recycling factor possible key to new class of antibiotics
8. Bacteria spill their guts to aid researchers in quest for new antibiotics
9. Molecule that blocks key bacterial enzyme may lead to new antibiotics
10. Does antibiotic use contribute to allergies?
11. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... City, KS. (PRWEB) , ... April 28, 2017 ... ... service contract research organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) ... having validated a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets ...
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a ... 43North Startup Competition, has truly taken their cancer research out of this world. ... experiments from Cape Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Summit ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA on September 27-28, ... to learn about the latest advances in the treatment of various types of ...
Breaking Biology Technology:
Cached News: